An English literature review revealed that the likelihood of developing an infection is high in the first 6 months of initiating anti-TNF agents but declines after 24–36 months in patients with rheumatic arthritis.[9] Our patient presented with odontogenic brain abscess after the third injection of 40-mg adalimumab received at a 2-week interval. The gene discussed is TNF; the disease is infection.